Press Releases

SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor

SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General

Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and International Conference on Malignant Lymphoma (ICML) Lugano ALLO-501/501A Demonstrated Rates of Durable

Conference Call and Webcast Scheduled for 2:00 PM PT / 5:00 PM ET SOUTH SAN FRANCISCO, Calif. , July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today

Presentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose Regimen Results Indicate an Off-the-Shelf Allogeneic CAR T Can Potentially Deliver Durable Complete Responses

SOUTH SAN FRANCISCO, Calif. , June 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, announced that its Chief Financial Officer, Eric T.

Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR T

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen 67% Overall Response Rate (ORR) and 58%

SOUTH SAN FRANCISCO, Calif. , May 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in three upcoming investor

Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif. , May 11, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the